These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 41040)

  • 41. Concentration and reactivity of the sulphydryl group population on the membrane of intact erythrocytes in patients with rheumatoid arthritis.
    Chilles C; Mulheron M; McCrae FM; Reglinksi J; Smith WE; Brzeski M; Sturrock RD
    Ann Rheum Dis; 1990 Sep; 49(9):668-71. PubMed ID: 2241282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The activity of natural killer cells in patients with rheumatoid arthritis: I. The effect of drugs used in vivo.
    Russell AS; Miller C
    Clin Exp Rheumatol; 1984; 2(3):227-9. PubMed ID: 6442225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of increased serum sulphydryl content on titre of rheumatoid factor.
    Jaffe IA; Merryman P
    Ann Rheum Dis; 1968 Jan; 27(1):14-8. PubMed ID: 5640838
    [No Abstract]   [Full Text] [Related]  

  • 44. A review of possible mechanisms of action of the antirheumatic drug, alclofenac.
    Aylward M
    Curr Med Res Opin; 1975; 3(5):249-63. PubMed ID: 241594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiarthritic drugs containing thiol groups scavenge hypochlorite and inhibit its formation by myeloperoxidase from human leukocytes. A therapeutic mechanism of these drugs in rheumatoid arthritis?
    Cuperus RA; Muijsers AO; Wever R
    Arthritis Rheum; 1985 Nov; 28(11):1228-33. PubMed ID: 2998407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis.
    Nagashima M; Wauke K; Hirano D; Ishigami S; Aono H; Takai M; Sasano M; Yoshino S
    Rheumatology (Oxford); 2000 Nov; 39(11):1255-62. PubMed ID: 11085806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term low dose ticlopidine treatment in rheumatoid arthritis: effects on serum sulphydryl levels, technetium index, erythrocyte sedimentation rate, and clinical disease activity.
    Grimaldi MG
    Eur J Clin Pharmacol; 1985; 29(2):165-8. PubMed ID: 3000794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The pharmacology of antirheumatic drugs.
    Parnham MJ
    Agents Actions Suppl; 1984; 14():153-69. PubMed ID: 6382972
    [No Abstract]   [Full Text] [Related]  

  • 49. Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis.
    Beyeler C; Frey BM; Bird HA
    Br J Rheumatol; 1997 Jan; 36(1):54-8. PubMed ID: 9117175
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trace elements and acute phase reactants in gold treated rheumatoid arthritis patients.
    Menard HA; Barrette M; Lamoureux G; Lecomte R; Paradis P; Monaro S; Drapeau G
    J Rheumatol Suppl; 1979; 5():143-8. PubMed ID: 114644
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does second-line therapy affect the radiological progression of rheumatoid arthritis?
    Pullar T; Hunter JA; Capell HA
    Ann Rheum Dis; 1984 Feb; 43(1):18-23. PubMed ID: 6421253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. D-penicillamine-induced increase in intracellular glutathione correlating to clinical response in rheumatoid arthritis.
    Munthe E; Kåss E; Jellum E
    J Rheumatol Suppl; 1981; 7():14-9. PubMed ID: 6785436
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impaired suppressor cell activity due to surface sulphydryl oxidation in rheumatoid arthritis.
    Brown-Galatola CH; Hall ND
    Br J Rheumatol; 1992 Sep; 31(9):599-603. PubMed ID: 1388084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Gold compounds and D-penicillamine for therapy of rheumatoid arthritis].
    Miyamoto S; Inoue T
    Nihon Rinsho; 1992 Mar; 50(3):515-20. PubMed ID: 1588740
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pharmacological consequences of the binding of anti-rheumatic drugs to plasma proteins in the treatment of rheumatoid arthritis.
    McArthur JN
    Agents Actions; 1979 Jun; 9(2):212-6. PubMed ID: 382804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Anti-inflammatory or antirheumatic agents? Pharmacological activity and therapeutic effectiveness of non-steroid anti-inflammatory drugs: comparative study. III].
    Mariani L; Baratelli M
    Clin Ter; 1980 Feb; 92(4):331-58. PubMed ID: 7004749
    [No Abstract]   [Full Text] [Related]  

  • 57. Delayed hypersensitivity to tuberculin in rats: effects of antirheumatic drugs.
    Bramm E; Binderup L; Arrigoni-Martelli E
    Acta Pharmacol Toxicol (Copenh); 1979 Jan; 44(1):75-80. PubMed ID: 104548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A comparative evaluation of parenteral and oral preparations of gold and D-penicillamine in the treatment of rheumatoid nephropathy].
    Chichasova NV; Kanevskaia MZ; Slobodina GA; Varshavskiĭ VA; Krel' OV; Krel' AA
    Ter Arkh; 1991; 63(5):97-101. PubMed ID: 1679571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse reactions to the principal drugs used in rheumatoid arthritis--a review.
    Franchimont P; Heynen G; Hauwaert CH
    J Rheumatol Suppl; 1978; 4():85-92. PubMed ID: 282449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.
    Ward JR
    Am J Med; 1988 Oct; 85(4A):39-44. PubMed ID: 3052055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.